HighMark Wealth Management’s bluebird bio BLUE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-11
| Closed | -$54 | – | 618 |
|
|
2025
Q1 | $54 | Hold |
11
| – | – | ﹤0.01% | 565 |
|
|
2024
Q4 | $92 | Sell |
11
-1
| -8% | -$9 | ﹤0.01% | 562 |
|
|
2024
Q3 | $119 | Hold |
12
| – | – | ﹤0.01% | 578 |
|
|
2024
Q2 | $226 | Hold |
12
| – | – | ﹤0.01% | 561 |
|
|
2024
Q1 | $294 | Hold |
12
| – | – | ﹤0.01% | 543 |
|
|
2023
Q4 | $317 | Hold |
12
| – | – | ﹤0.01% | 544 |
|
|
2023
Q3 | $699 | Hold |
12
| – | – | ﹤0.01% | 521 |
|
|
2023
Q2 | $757 | Hold |
12
| – | – | ﹤0.01% | 515 |
|
|
2023
Q1 | $731 | Hold |
12
| – | – | ﹤0.01% | 549 |
|
|
2022
Q4 | $1.59K | Hold |
12
| – | – | ﹤0.01% | 447 |
|
|
2022
Q3 | $1K | Hold |
12
| – | – | ﹤0.01% | 460 |
|
|
2022
Q2 | $1K | Hold |
12
| – | – | ﹤0.01% | 461 |
|
|
2022
Q1 | $1K | Hold |
12
| – | – | ﹤0.01% | 472 |
|
|
2021
Q4 | $2K | Sell |
12
-6
| -33% | -$1.42K | ﹤0.01% | 436 |
|
|
2021
Q3 | $4K | Hold |
18
| – | – | ﹤0.01% | 380 |
|
|
2021
Q2 | $7K | Hold |
18
| – | – | 0.01% | 299 |
|
|
2021
Q1 | $7K | Buy |
18
+9
| +100% | +$4.43K | 0.01% | 287 |
|
|
2020
Q4 | $5K | Hold |
9
| – | – | ﹤0.01% | 322 |
|
|
2020
Q3 | $6K | Hold |
9
| – | – | 0.01% | 287 |
|
|
2020
Q2 | $7K | Hold |
9
| – | – | 0.01% | 256 |
|
|
2020
Q1 | $5K | Buy |
+9
| New | +$8.77K | 0.01% | 222 |
|
Other funds holding BLUE
HighMark Wealth Management's BLUE Position: Q2 2025 in Review
HighMark Wealth Management sold out of bluebird bio (BLUE) in Q2 2025, closing a stake of 11 shares — an estimated $54 sold.
HighMark Wealth Management first reported a position in BLUE in Q1 2020 and held it in 21 quarters. The position peaked at $7K in Q2 2021. 3 funds tracked by Wall St. Rank hold BLUE as of Q2 2025.
- HighMark Wealth Management reported no remaining bluebird bio position as of Q2 2025 after selling out during the quarter.
- HighMark Wealth Management sold 11 bluebird bio shares in Q2 2025, an estimated $54.
- HighMark Wealth Management first reported a position in bluebird bio in Q1 2020 and held it in 21 quarters.
- HighMark Wealth Management's bluebird bio position peaked at $7K in Q2 2021.
- 3 funds tracked by Wall St. Rank held bluebird bio as of Q2 2025.
Based on HighMark Wealth Management's 13F filing for Q2 2025, filed 21 Jul 2025.